2616.HK
CSTONE PHARMA-B
HK$8.05
+5.78%
2026-05-29
About CSTONE PHARMA-B
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Key Fundamentals
Forward P/E
-44.23
EPS (TTM)
HK$-0.36
ROE
-89.1%
Revenue Growth (YoY)
43.8%
Profit Margin
-162.1%
Debt/Equity
56.51
Price/Book
16.67
Beta
0.25
Market Cap
HK$12.87B
Avg Volume (10D)
6.2M
Recent Breakout Signals
No recent breakout signals detected for 2616.HK.
Recent Price Range (60 Days)
60D High
HK$10.41
60D Low
HK$5.80
Avg Volume
13.6M
Latest Close
HK$8.05
Get breakout alerts for 2616.HK
Sign up for Breakout Scanner to receive daily notifications when 2616.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
CSTONE PHARMA-B (2616.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 2616.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 2616.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.